Skip to content
value.today

Globeimmune Inc.

Total raised
$41 M
4 rounds on record
Latest round
$8 M
Jan 2014
First round on record
Mar 2009
Today
Went public
See the company page

Globeimmune Inc. is listed today as Globeimmune, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Globeimmune Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2017$2 MPrivate placement after listing$2 to $10 million

Globeimmune Inc.: Private sale, Mar 2017

Investors in this round

1 investor had bought by the notice of Mar 23, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Globeimmune Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • C. Jeffrey Dekker · Executive Officer
  • Charles Jeffrey Kim · Director
  • Jerel Jeffrey Banks · Director
  • Timothy C. Rodell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Consideration consisted of $100,000 in cash and purchaser securities in the aggregate value of $2.0 million.”

Signed by C. Jeffrey Dekker, President & Treasurer. Source: SEC Form D, newest notice filed Mar 23, 2017. Read the notice at the SEC.

equitySEC
Jan 2014$8 MNo. 4$2 to $10 million

Globeimmune Inc.: Raise no. 4, Jan 2014

Investors in this round

110 investors had bought by the notice of Jun 10, 2014: 104 accredited, 6 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Globeimmune Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Units consisting of convertible promissory notes and warrants to purchase equity securities of the Issuer.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$798,600
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • C Jeffrey Dekker · Executive Officer
  • Kirk A Christoffersen · Executive Officer
  • Timothy C Rodell · Executive Officer, Director
  • Augustine J Lawlor · Director
  • Dan J Mitchell · Director
  • J William Freytag · Director
  • Paul A Mieyal · Director
  • Pennina J Safer · Director
  • Ralph E Christoffersen · Director
  • S Edward Torres · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Aegis Capital Corp. (CRD 15007) · New York, New YorkSold in all US states
  • Kingsbury Capital LLC (CRD 147102) · Evanston, IllinoisSold in CA, IL, NV, OK, WI

Remarks in the notice

  • On fees: “Cash fee equal to 10% of the gross proceeds (3% for Issuer introduced investors) & a non-accountable expense allowance of 2% of the gross proceeds. Plus a warrant for shares of common stock (number of shares & exercise price not determinable at issue).”

Signed by C. Jeff Dekker, VP, Finance. Source: SEC Form D and 1 amendment, newest notice filed Jun 10, 2014. Read the notice at the SEC.

debt, optionsSEC
Jan 2010$18 MNo. 3$10 to $50 million

Globeimmune Inc.: Raise no. 3, Jan 2010

Investors in this round

27 investors had bought by the notice of Feb 3, 2010: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Globeimmune Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David C Apelian · Executive Officer
  • Jeff C Rona · Executive Officer
  • John C Frenz · Executive Officer
  • Timothy C Rodell · Executive Officer, Director
  • Augustine William Lawlor · Director
  • Dan J Mitchell · Director
  • Darren C Carroll · Director
  • Ehud William Geller · Director
  • J. William Freytag · Director
  • Paul William Mieyal · Director
  • Ralph C Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeff Rona, Chief Business Officer & Treasurer. Source: SEC Form D and 1 amendment, newest notice filed Feb 3, 2010. Read the notice at the SEC.

equitySEC
May 2009$13 MNo. 2$10 to $50 million

Globeimmune Inc.: Raise no. 2, May 2009

Investors in this round

1 investor had bought by the notice of May 20, 2009: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Globeimmune Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $13 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in De

People named in the notice

  • David Apelian · Executive Officer
  • Jeff Rona · Executive Officer
  • John Frenz · Executive Officer
  • Timothy C Rodell · Executive Officer, Director
  • Augustine Lawlor · Director
  • Dan J Mitchell · Director
  • Darren Carroll · Director
  • Ehud Geller · Director
  • J. William Freytag · Director
  • Paul Mieyal · Director
  • Ralph Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeff Rona, Chief Business Officer & Treasurer. Source: SEC Form D, newest notice filed May 20, 2009. Read the notice at the SEC.

equity, optionsSEC
Mar 2009$3 MNo. 1$2 to $10 million

Globeimmune Inc.: Raise no. 1, Mar 2009

Investors in this round

17 investors had bought by the notice of Mar 17, 2009: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Globeimmune Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in De

People named in the notice

  • David Apelian · Executive Officer
  • Jeff Rona · Executive Officer
  • John Frenz · Executive Officer
  • Timothy C Rodell · Executive Officer, Director
  • Augustine Lawlor · Director
  • Dan J Mitchell · Director
  • Darren Carroll · Director
  • Ehud Geller · Director
  • J. William Freytag · Director
  • Paul Mieyal · Director
  • Ralph Christoffersen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeff Rona, Chief Business Officer & Treasurer. Source: SEC Form D, newest notice filed Mar 17, 2009. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Globeimmune Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2017).

    SEC Form D · Mar 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2017

That is all the official record says: Globeimmune Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Globeimmune Inc. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Globeimmune Inc.
InvestorKindAmountRoundRoleSource
Celgene Corp /de/Companynot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Celgene International IncCompanynot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
HealthCare Partners VII, L.P.Fund or asset managernot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Healthcare Ventures VII LPVenture capitalnot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Morgenthaler Management Partners VII, LLCFund or asset managernot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Morgenthaler Partners VII LPFund or asset managernot statednot statedHeld Series A, B, C and E preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 110 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Globeimmune Inc.
NameRoleNamed in
C. Jeffrey DekkerExecutive officerMar 2017
C Jeffrey DekkerExecutive officerJun 2014
Kirk A ChristoffersenExecutive officerJun 2014
Timothy C RodellExecutive officerJun 2014
David C ApelianExecutive officerFeb 2010
Jeff C RonaExecutive officerFeb 2010
John C FrenzExecutive officerFeb 2010
David ApelianExecutive officerMay 2009
Jeff RonaExecutive officerMay 2009
John FrenzExecutive officerMay 2009
Charles Jeffrey KimDirectorMar 2017
Jerel Jeffrey BanksDirectorMar 2017
Timothy C. RodellDirectorMar 2017
Augustine J LawlorDirectorJun 2014
Dan J MitchellDirectorJun 2014
J William FreytagDirectorJun 2014
Paul A MieyalDirectorJun 2014
Pennina J SaferDirectorJun 2014
Ralph E ChristoffersenDirectorJun 2014
S Edward TorresDirectorJun 2014
Timothy C RodellDirectorJun 2014
Augustine William LawlorDirectorFeb 2010
Darren C CarrollDirectorFeb 2010
Ehud William GellerDirectorFeb 2010
J. William FreytagDirectorFeb 2010
Paul William MieyalDirectorFeb 2010
Ralph C ChristoffersenDirectorFeb 2010
Augustine LawlorDirectorMay 2009
Darren CarrollDirectorMay 2009
Ehud GellerDirectorMay 2009
Paul MieyalDirectorMay 2009
Ralph ChristoffersenDirectorMay 2009

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.